Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbott Laboratories (ABT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 130,874,584
  • Shares Outstanding, K 1,756,470
  • Annual Sales, $ 30,578 M
  • Annual Income, $ 2,368 M
  • 60-Month Beta 1.13
  • Price/Sales 4.25
  • Price/Cash Flow 15.38
  • Price/Book 4.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.80
  • Number of Estimates 10
  • High Estimate 0.81
  • Low Estimate 0.78
  • Prior Year 0.73
  • Growth Rate Est. (year over year) +9.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.36 +2.97%
on 04/17/19
80.74 -7.72%
on 04/01/19
-3.46 (-4.44%)
since 03/22/19
3-Month
68.80 +8.30%
on 01/29/19
80.74 -7.72%
on 04/01/19
+3.02 (+4.22%)
since 01/22/19
52-Week
56.81 +31.16%
on 05/03/18
80.74 -7.72%
on 04/01/19
+15.32 (+25.88%)
since 04/20/18

Most Recent Stories

More News
Significant CAGR Growth to Be Achieved by Anal Fissure Treatment Market by Global Trends, Size, Growth Rate by 2023

The market is expected to reach the valuation of USD 2,526.5 million by the year 2023, by growing at a CAGR of 7.6% during the forecast period (2018- 2023).

VRX.TO : 30.80 (-3.33%)
BAYRY : 17.1500 (-0.17%)
ABT : 74.51 (+0.80%)
AGN : 140.26 (-0.04%)
ESALF : 55.0000 (-4.93%)
GSK : 39.68 (-0.43%)
Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?

Is (ABT) Outperforming Other Medical Stocks This Year?

ABT : 74.51 (+0.80%)
Latin American Countries Offer Unique Benefits to Cannabis Cultivators

FinancialBuzz.com News Commentary

ABT : 74.51 (+0.80%)
BBRRF : 0.5150 (-1.15%)
BBM.CN : 0.680 (-2.86%)
KHRNF : 2.3700 (unch)
Uptrend Call Working As Abbott Labs Stock Rises 2.2% (ABT)

SmarTrend identified an Uptrend for Abbott Labs (NYSE:ABT) on January 18th, 2019 at $71.26. In approximately 3 months, Abbott Labs has returned 2.25% as of today's recent price of $72.86.

ABT : 74.51 (+0.80%)
Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid

Abbott (ABT) reports strong and consistent EPD and Medical Devices performance organically in Q1.

ABT : 74.51 (+0.80%)
LMAT : 27.40 (+0.59%)
BIO : 293.49 (-0.22%)
DXCM : 116.61 (+2.03%)
Abbott (ABT) Surpasses Q1 Earnings and Revenue Estimates

Abbott (ABT) delivered earnings and revenue surprises of 3.28% and 0.91%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

ABT : 74.51 (+0.80%)
Abbott: 1Q Earnings Snapshot

ABBOTT PARK, Ill. (AP) _ Abbott Laboratories (ABT) on Wednesday reported first-quarter net income of $672 million.

ABT : 74.51 (+0.80%)
Blueberries Medical Appoints Former Abbott Laboratories/AbbVie Pharmaceutical Executive Eduardo Molinari as Chief Marketing Officer

Blueberries Medical Corp. (CSE: BBM) (OTCQB: BBRRF) (FRA: 1OA) (the "Company" or "Blueberries") a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce...

ABT : 74.51 (+0.80%)
BBRRF : 0.5150 (-1.15%)
BBM.CN : 0.680 (-2.86%)
ABBV : 78.15 (+0.75%)
Abbott Reports First-Quarter 2019 Results

Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2019.

ABT : 74.51 (+0.80%)
5 Spectacular Large Cap Earnings Charts

Which large cap earnings reports should you be watching this week?

NFLX : 377.34 (+4.71%)
ABT : 74.51 (+0.80%)
CSX : 78.82 (-0.19%)
ISRG : 491.06 (-7.01%)
TSM : 45.15 (-0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade ABT with:

Business Summary

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

See More

Key Turning Points

2nd Resistance Point 75.64
1st Resistance Point 75.07
Last Price 74.51
1st Support Level 73.47
2nd Support Level 72.44

See More

52-Week High 80.74
Last Price 74.51
Fibonacci 61.8% 71.60
Fibonacci 50% 68.78
Fibonacci 38.2% 65.95
52-Week Low 56.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar